This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Major Crispin Nicholas Black (511814), Welsh Guards. Major Alexander Thomas Boyd (496287), The Royal Logistic Corps. Major Joseph Bright (518051), Adjutant General's Corps (SPS). 24652448 Sergeant (Acting Staff Sergeant) David William Brown, The Royal Logistic Corps. Major Malcolm Hugh Peter Buchanan (495490), The Royal Logistic Corps. 24330851 Warrant Officer Class 1 Andrew Kenneth George Card, The Royal Logistic Corps. Major Steven Cheetham, , (495676), Corps of Royal Engineers (Volunteers), Territorial Army. Acting Lieutenant Colonel John Cobb (448934), Stonyhurst College Combined Cadet Force, Territorial Army. Major Gavin Terence Collinson (501572), The Royal Logistic Corps. 24563002 Staff Sergeant Anthony Raymond Cooper, Adjutant General's Corps (RMP). 24185755 Warrant Officer Class 1 Alan John Crawford, Scots Guards. 24198806 Warrant Officer Class 1 William Crook, Adjutant General's Corps (SPS). 23962020 Staff Sergeant Graham Stuart Daniell, Corps of Royal Electrical and Mechanical Engineers. 24511850 Sergeant (Acting Colour Sergeant) Stephen Denham, The Worcestershire and Sherwood Foresters Regiment. 24072935 Staff Sergeant John James Flannigan, The Light Dragoons. Captain John William Alexander France, , (508406), The Green Howards (Volunteers), Territorial Army. 24750683 Corporal Michael Sean Gill, Corps of Royal Engineers. Major Richard Duncan Brownrigg Gordon (513813), Adjutant General's Corps (ETS). Major Paul Anthony Philip Griffiths (517124) Royal Regiment of Artillery. Captain (Queen's Gurkha Officer) Dharmendra Gurung (537028), The Royal Gurkha Rifles.
Cystine/glutamate transporter is an antiporter that in humans is encoded by the SLC7A11 gene. The SLC7A11 gene encodes a sodium-independent cystine-glutamate antiporter that is chloride dependent, also known as xCT. Along with a heavy chain subunit from SLC3A2, the SLC7A11 light chain comprises system Xc-, which is the functional cystine-glutamate antiporter. While the SLC3A2 heavy chain is a chaperone for many other light chains that participate in amino acid transport, the SLC7A11 light chain is specific for system Xc-, and the terms xCT/SLC7A11 and system Xc- are used interchangeably in much of the literature. SLC7A11 couples the uptake of one molecule of cystine with the release of one molecule of glutamate, and therefore it plays an important role in glutathione production throughout nervous and non-nervous tissues. In the nervous system, SLC7A11 regulates synaptic activity by stimulating extrasynaptic receptors and performs nonvesicular glutamate release. This gene is highly expressed by astrocytes. The expression of Xc- was detected throughout the brain with higher expression found in the basolateral amygdala, the retina and the prefrontal cortex. The inhibition of system Xc- has been found to alter a number of behaviors, which suggests that it plays a key role in excitatory signaling. SLC7A11 has been found to accept cysteine hydropersulfide as an alternative substrate, exchanging one molecule of cysteine hydropersulfide for one molecule of cystine under the basal concentration gradients for these species.
=== Structural evolution === De novo proteins typically exhibit less well-defined secondary and three-dimensional structures, often lacking rigid folding but having extensive disordered regions. Quantitative analyses are still lacking on the evolution of secondary structural elements and tertiary structures over time. As structure is usually more conserved than sequence, comparing structures between orthologs could provide deeper insides into de novo gene emergence and evolution and help to confirm these genes as true de novo genes. Nevertheless, so far only very few de novo proteins have been structurally and functionally characterized, especially due to problems with protein purification and subsequent stability. Progresses have been made using different purification tags, cell types and chaperones. The 'antifreeze glycoprotein' (AFGP) in Arctic codfishes prevents their blood from freezing in arctic waters. Bsc4, a short non-essential de novo protein in yeast, has been shown to be built mainly by β-sheets and has a hydrophobic core. It is associated to DNA repair under nutrient-deficient conditions. The Drosophila de novo protein Goddard has been characterized for the first time in 2017. Knockdown Drosophila melanogaster male flies were not able to produce sperm. Recently, it could be shown that this lack was due to failure of individualization of elongated spermatids.
post-mastectomy re-creation of the breast(s); trauma damage (blunt, penetrating), disease (breast cancer), and explantation deformity (empty breast-implant socket). congenital defect correction: micromastia, tuberous breast deformity, and Poland's syndrome. primary augmentation: the aesthetic enhancement (contouring) of the size, form, and feel of the breasts. The application of the adipose fat tissue as autologous filler for injection to correct bodily defects and for breast augmentation was developed by Melvin Bircoll by way of the fat-injection method. In 1987, the surgeon Eduardo Krulig injected fat-grafts with a syringe and a blunt-tip needle, and also used a disposable fat trap to facilitate the collection of body fat and to ensure the sterility of the harvested adipocyte tissue. The doctors J. Newman and J. Levin designed a lipo-injector gun with a gear-driven plunger for the even injection of autologous fat-tissue to the breast-implant pocket. The design of the lipo-injector gun featured a ratchet-gear for accurately emplacing the fat-grafts to the breast-implant pocket; the trigger action injected 0.1 cm3 of filler. Non-surgical, fat-graft augmentations of the breast employs adipocyte fat from elsewhere in the body of the woman (up to 300 ml of body fat) with three injections of equal volume, is injected to the subpectoral space and to the intrapectoral space of the pectoralis major muscle, and to the submammary space in order to achieve a breast of natural appearance and contour.
=== Supplements === The use of certain amino acids may slow muscle breakdown by providing the body with the building blocks needed for metabolism of muscle and glucose. Specifically, leucine and valine may block muscle breakdown. Glutamine is used in oral supplements for people with advanced cancer or HIV/AIDS. β-hydroxy β-methylbutyrate (HMB) is a molecule that comes from leucine that promotes muscle growth. Studies show positive results for chronic pulmonary disease, hip fracture, and in AIDS-related and cancer-related cachexia. However, it is often studied along with other nutrients, making it difficult to assess its effects alone. Creatine supplementation may help reduce muscle wasting, though more research is needed.
Sources: en.wikipedia.org
Pushing Cool: Big Tobacco, Racial Marketing, and the Untold Story of the Menthol Cigarette (2021) excerpt Werner, Carl Avery. Tobaccoland: A book about tobacco; its history, legends, literature, cultivation, social and hygienic influences, commercial development, industrial processes and governmental regulation. (1922) online Winkler, John K. Tobacco tycoon, the story of James Buchanan Duke (1942) online Woofter Jr. T.J. The Plight of Cigarette Tobacco (1931) Zhou, Xun Yu, Gilman, Sander L. (2004). Smoke: a global history of smoking. London: Reaktion Books. ISBN 978-1-86189-200-3.
Vicine is an alkaloid glycoside found mainly in fava beans, which are also called broad beans (Vicia faba). Vicine is toxic in individuals who have a hereditary loss of the enzyme glucose-6-phosphate dehydrogenase. It causes haemolytic anaemia, called favism. The formation of vicine in Vicia faba has been studied, but this natural formation has not yet been found.
=== Immune modulation and infection === Semaglutide appears to influence the immune system through a complex gut-brain-immune network. The activation of central neuronal GLP-1 receptors by semaglutide signals through the endogenous opioid and adrenergic systems to suppress peripheral inflammation. In conditions like obesity, compromised gut barriers can allow bacterial lipopolysaccharides (LPS, or endotoxins) to enter the bloodstream, triggering severe immune responses via TLR4 receptors. Semaglutide blunts this LPS-induced release of pro-inflammatory cytokines. Moreover, in animal models of polymicrobial sepsis, semaglutide has been shown to decrease bacterial loads in multiple organs and promote the homeostasis of immunoregulatory regulatory T cells (Tregs) via the activation of FOXP3.
Enantiomeric impurities also impede RNA replication and chain elongation, processes central to both modern cellular processes like transcription and the RNA world hypothesis. As homochirality is ubiquitous in extant biology, a key question in origins of life and prebiotic chemistry research is how biological homochirality could have arisen from racemic mixtures of the simple chemical building blocks of life. Many mechanisms for the origin of homochirality have been proposed. Some of these models propose three distinct steps: a mirror-symmetry breaking mechanism to create a minute enantiomeric imbalance (enantiomeric excess or ee) from a racemic mixture, subsequent chiral amplification to achieve a larger ee or full homochirality (i.e., ee=100%), and finally chiral transmission/propagation to transfer chirality from one set of molecules to another. In addition, another important consideration is the environmental plausibility of proposed mechanisms — whether a symmetry breaking, amplification, or propagation process could occur over relevant timescales and using only materials that could feasibly be available prebiotically under early Earth conditions.
==== Contingency Management Therapy ==== Contingency Management Therapy (CMT) employs similar principles as operant behavioral conditioning, such as using incentives to reach certain goals (e.g., verified abstinence, usually in the form of urine drug testing). This form of psychotherapy has the strongest, most robust empirical support for treating drug addiction. Outpatient clients are shown to have improved medication compliance, retention, and abstinence when using voucher-based incentives. One way this is implemented is to offer take-home privileges for methadone programs. Despite its effectiveness during treatment, effects tend to wane once terminated. Additionally, the cost barrier limits its application in the clinical community.
Sources: en.wikipedia.org
The safety of pivekimab sunirine was evaluated in a pooled population of 116 participants who received the approved dose of pivekimab sunirine. This pooled safety population included the 84 participants with blastic plasmacytoid dendritic cell neoplasm as well as additional enrolled participants with other CD123-positive blood or bone marrow cancers treated at the approved dose.
=== Tray drying === A tray dryer is similar to a convection drier, which is placed in enclosed, insulated chambers and trays on top of each other in the tray. Input materials are batch-fed, placed in trays, and loaded into ovens for drying. Dryers are used in processing where drying and heating are important parts of the industrial manufacturing process, like dried fruits. Tray drying means dehydrating small pieces of fruit from a source of hot, dry air or the sun until they are dry enough to store at ambient temperature with minimal spoilage. Despite its poor re-hydration properties and shrunken appearance, this process requires a short period of time along with controlled humidity and heated air.
expedited border control programme for low-risk travellers holding Canadian or U.S. citizenship or permanent residence. Membership requires approval by Canadian and U.S. authorities and entitles members to dedicated RFID-enabled lanes when crossing the land border. A NEXUS card can also be utilised as a travel document between the two countries and entitles passengers to priority border control facilities in Canada and Global Entry facilities in the U.S. Free and Secure Trade (FAST) is a similar programme for commercial drivers and approved importers, reducing the amount of customs checks conducted at the border and expediting the border control process. When entering the U.S. by air, holders of NEXUS cards may use Global Entry kiosks to clear border controls at participating airports SENTRI: SENTRI is a programme similar to NEXUS for U.S. and Mexican citizens that also allows members to register their cars for expedited land-border controls. Unlike NEXUS, SENTRI is administered solely by the American government and does not provide expedited controls when entering Mexico. When entering the United States by land from Canada, a NEXUS card can be used, but not the other way around. Individuals holding a NEXUS card may additionally register their cars for expedited land border controls under SENTRI. When entering the United States by air, holders of SENTRI cards may use Global Entry kiosks to clear border controls at participating airports
In literature the positive psychological approach to personality is correlated often with the concepts of personal/psychosocial development and human development, balanced, strong, mature and proactive personality, character strengths and virtues, evidenced by traits like optimism and energy, pragmatism, active consciousness, assertiveness, free and powerful will, self-determination and self-realization, personal and social autonomy, social adaptability, personal and social efficiency, interpersonal development and professional development, proactive and positive thinking, humanity, empathy and love, emotional intelligence, subjective/psychological well-being, extraversion, happiness, positive emotions. Many tools for psychological wellness have entered popular culture via the personal development and self help industry. Positive music, will lower distress and pain, but news media consumption is detrimental for happiness. One exception is motivational media, for it has been found that inspiration helps with creativity, productivity and happiness. Reading self help books is associated with higher well-being, however, there is poor evidence on life coaching. Proactive laughter as in laughter yoga increases mood and improves pain tolerance. Smiling increases attractiveness, calmness in stressful situations, retrieval of positive memories, likeability, happiness, perceived happiness (by others), perceived politeness/relaxedness/carefreeness, and perceived honesty but also perceived stupidity.
Bukele registered as a presidential pre-candidate on 26 June 2023 with Nuevas Ideas; Ulloa registered as Bukele's vice-presidential pre-candidate. Nuevas Ideas nominated Bukele and Ulloa as their presidential and vice-presidential candidates on 9 July. The party began registering Bukele and Ulloa's candidacies with the TSE on 26 October, the last day to do so. On 3 November 2023, the TSE registered their candidacies amidst opposition requests to reject Bukele's candidacy. On 30 November 2023, the Legislative Assembly granted Bukele and Ulloa leaves of absence to focus on their re-election campaign. The leave went into effect the following day and Bukele's presidential powers were suspended. The Legislative Assembly named Claudia Rodríguez de Guevara, Bukele's presidential secretary, as the presidential designate; Rodríguez was the first woman in Salvadoran history to hold presidential power. Her appointment was criticized by some lawyers and opposition politicians as unconstitutional. Including Bukele, there were six presidential candidates in the 2024 election. His primary opponents were ARENA's Joel Sánchez, a businessman, and the FMLN's Manuel Flores, a former legislator. Bukele led Sánchez and Flores by large margins in opinion polling before the election. Bukele promised to maintain the gang crackdown, invest in infrastructure projects, and promote economic growth during his second term. On 4 February 2024, he won re-election with 84.65 percent of the vote. Bukele was the first Salvadoran president to be re-elected since Maximiliano Hernández Martínez in 1944.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。